Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
116 hedge funds and large institutions have $1.36B invested in Clovis Oncology, Inc. in 2013 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 30 reducing their positions, and 18 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 30
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
6% more funds holding
Funds holding: 109 → 116 (+7)
5% less capital invested
Capital invested by funds: $1.43B → $1.36B (-$66.8M)
6% less call options, than puts
Call options by funds: $18.1M | Put options by funds: $19.3M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$27.9M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$27.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$18.9M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$23.4M |
| 2 |
DM
Deerfield Management
New York
|
-$20.5M |
| 3 |
QF
QVT Financial
New York
|
-$19.3M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$16.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$15.8M |
CLVS Hedge Fund Activity: Q3 2013 in Review
116 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2013, worth a combined $1.36B — down 4.7% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CLVS positions and 18 closed out — a net gain of 7 holders — while 53 added to existing stakes and 30 trimmed.
The largest buyer was SAC Capital Advisors, adding an estimated $27.9M. The largest seller was Millennium Management, cutting an estimated $23.4M.
- 116 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2013, up from 109 in Q2 2013.
- Funds reported $1.36B of Clovis Oncology, Inc. stock for Q3 2013, down 4.7% quarter-over-quarter.
- 25 funds opened new Clovis Oncology, Inc. positions in Q3 2013 and 18 closed out, a net change of +7 holders.
- The largest Clovis Oncology, Inc. buyer in Q3 2013 was SAC Capital Advisors, an estimated $27.9M added.
- The largest Clovis Oncology, Inc. seller in Q3 2013 was Millennium Management, an estimated $23.4M sold.
Based on aggregated 13F filings for Q3 2013.